APO Research
Talk to an analyst

APO RESEARCH · REPORT

Semi-Solid Dosage Form

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Semi-Solid Dosage Form Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025193 pages

Choose your research edition.

Industry ResearchSemi-Solid Dosage Form Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Semi-Solid Dosage Form Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Semi-Solid Dosage Form Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Semi-Solid Dosage Form Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Semi-Solid Dosage Form Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Semi-Solid Dosage Form market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Semi-Solid Dosage Form is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Semi-Solid Dosage Form is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Semi-Solid Dosage Form is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Semi-Solid Dosage Form is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Semi-Solid Dosage Form include Aclaris Therapeutics, Inc., Akorn Inc. (US), Allergan plc, Almirall, S.A, Bausch Health Companies, Biofrontera, Inc., Cipla Ltd, Crescita Therapeutics Inc. and Crown Laboratories Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Semi-Solid Dosage Form market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Semi-Solid Dosage Form and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Semi-Solid Dosage Form sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Semi-Solid Dosage Form market size, projected growth trends, production technologies, key applications, and end-use industries.

Semi-Solid Dosage Form Segment by Company

Aclaris Therapeutics, Inc.

Akorn Inc. (US)

Allergan plc

Almirall, S.A

Bausch Health Companies

Biofrontera, Inc.

Cipla Ltd

Crescita Therapeutics Inc.

Crown Laboratories Inc.

Encore Dermatology, Inc.

Glenmark Pharmaceuticals

Hisamitsu Pharmaceutical

Ingenus Pharmaceuticals

LEO Pharma

Mylan N.V.

Novartis AG

Perrigo Pharma

Taro Pharmaceutical Industries Ltd.

Teligent Pharma

Bayer AG

GlaxoSmithKline plc

Merck & Co

Johnson & Johnson

Nestlé SA

Sun Pharmaceuticals

Semi-Solid Dosage Form Segment by Type

Ointments

Gels

Others

Semi-Solid Dosage Form Segment by Application

Nasal Cavity

Skin

Vaginal Cavity

Rectal Cavity

Others

Semi-Solid Dosage Form Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Semi-Solid Dosage Form market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Semi-Solid Dosage Form and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Semi-Solid Dosage Form.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Semi-Solid Dosage Form market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Semi-Solid Dosage Form manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Semi-Solid Dosage Form in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Semi-Solid Dosage Form in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Semi-Solid Dosage Form Industry Trends Table 2. Semi-Solid Dosage Form Industry Drivers Table 3. Semi-Solid Dosage Form Industry Opportunities and Challenges Table 4. Semi-Solid Dosage Form Industry Restraints Table 5. Global Semi-Solid Dosage Form Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Semi-Solid Dosage Form Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Semi-Solid Dosage Form Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Semi-Solid Dosage Form Sales Market Share by Manufacturers Table 9. Global Semi-Solid Dosage Form Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Semi-Solid Dosage Form Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Semi-Solid Dosage Form Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Semi-Solid Dosage Form Manufacturers, Product Type & Application Table 13. Global Semi-Solid Dosage Form Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Semi-Solid Dosage Form by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ointments Table 17. Major Manufacturers of Gels Table 18. Major Manufacturers of Others Table 19. Global Semi-Solid Dosage Form Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Semi-Solid Dosage Form Sales by Type (2021-2026) & (K Units) Table 21. Global Semi-Solid Dosage Form Sales by Type (2027-2032) & (K Units) Table 22. Global Semi-Solid Dosage Form Sales Market Share by Type (2021-2026) Table 23. Global Semi-Solid Dosage Form Sales Market Share by Type (2027-2032) Table 24. Global Semi-Solid Dosage Form Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Semi-Solid Dosage Form Revenue by Type (2021-2026) & (K Units) Table 26. Global Semi-Solid Dosage Form Revenue by Type (2027-2032) & (K Units) Table 27. Global Semi-Solid Dosage Form Revenue Market Share by Type (2021-2026) Table 28. Global Semi-Solid Dosage Form Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Nasal Cavity Table 30. Major Manufacturers of Skin Table 31. Major Manufacturers of Vaginal Cavity Table 32. Major Manufacturers of Rectal Cavity Table 33. Major Manufacturers of Others Table 34. Global Semi-Solid Dosage Form Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Semi-Solid Dosage Form Sales by Application (2021-2026) & (K Units) Table 36. Global Semi-Solid Dosage Form Sales by Application (2027-2032) & (K Units) Table 37. Global Semi-Solid Dosage Form Sales Market Share by Application (2021-2026) Table 38. Global Semi-Solid Dosage Form Sales Market Share by Application (2027-2032) Table 39. Global Semi-Solid Dosage Form Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Semi-Solid Dosage Form Revenue by Application (2021-2026) & (K Units) Table 41. Global Semi-Solid Dosage Form Revenue by Application (2027-2032) & (K Units) Table 42. Global Semi-Solid Dosage Form Revenue Market Share by Application (2021-2026) Table 43. Global Semi-Solid Dosage Form Revenue Market Share by Application (2027-2032) Table 44. Global Semi-Solid Dosage Form Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Semi-Solid Dosage Form Sales by Region (2021-2026) & (K Units) Table 46. Global Semi-Solid Dosage Form Sales Market Share by Region (2021-2026) Table 47. Global Semi-Solid Dosage Form Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Semi-Solid Dosage Form Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Semi-Solid Dosage Form Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Semi-Solid Dosage Form Sales by Country (2021-2026) & (K Units) Table 51. North America Semi-Solid Dosage Form Sales by Country (2027-2032) & (K Units) Table 52. Europe Semi-Solid Dosage Form Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Semi-Solid Dosage Form Sales by Country (2021-2026) & (K Units) Table 54. Europe Semi-Solid Dosage Form Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Semi-Solid Dosage Form Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Semi-Solid Dosage Form Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Semi-Solid Dosage Form Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Semi-Solid Dosage Form Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Semi-Solid Dosage Form Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Semi-Solid Dosage Form Sales by Country (2027-2032) & (K Units) Table 61. Global Semi-Solid Dosage Form Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Semi-Solid Dosage Form Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Semi-Solid Dosage Form Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Semi-Solid Dosage Form Revenue Market Share by Region (2021-2026) Table 65. Global Semi-Solid Dosage Form Revenue Market Share by Region (2027-2032) Table 66. Aclaris Therapeutics, Inc. Company Information Table 67. Aclaris Therapeutics, Inc. Business Overview Table 68. Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Portfolio Table 70. Aclaris Therapeutics, Inc. Recent Development Table 71. Akorn Inc. (US) Company Information Table 72. Akorn Inc. (US) Business Overview Table 73. Akorn Inc. (US) Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Akorn Inc. (US) Semi-Solid Dosage Form Product Portfolio Table 75. Akorn Inc. (US) Recent Development Table 76. Allergan plc Company Information Table 77. Allergan plc Business Overview Table 78. Allergan plc Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Allergan plc Semi-Solid Dosage Form Product Portfolio Table 80. Allergan plc Recent Development Table 81. Almirall, S.A Company Information Table 82. Almirall, S.A Business Overview Table 83. Almirall, S.A Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Almirall, S.A Semi-Solid Dosage Form Product Portfolio Table 85. Almirall, S.A Recent Development Table 86. Bausch Health Companies Company Information Table 87. Bausch Health Companies Business Overview Table 88. Bausch Health Companies Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Bausch Health Companies Semi-Solid Dosage Form Product Portfolio Table 90. Bausch Health Companies Recent Development Table 91. Biofrontera, Inc. Company Information Table 92. Biofrontera, Inc. Business Overview Table 93. Biofrontera, Inc. Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Biofrontera, Inc. Semi-Solid Dosage Form Product Portfolio Table 95. Biofrontera, Inc. Recent Development Table 96. Cipla Ltd Company Information Table 97. Cipla Ltd Business Overview Table 98. Cipla Ltd Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Cipla Ltd Semi-Solid Dosage Form Product Portfolio Table 100. Cipla Ltd Recent Development Table 101. Crescita Therapeutics Inc. Company Information Table 102. Crescita Therapeutics Inc. Business Overview Table 103. Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Portfolio Table 105. Crescita Therapeutics Inc. Recent Development Table 106. Crown Laboratories Inc. Company Information Table 107. Crown Laboratories Inc. Business Overview Table 108. Crown Laboratories Inc. Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Crown Laboratories Inc. Semi-Solid Dosage Form Product Portfolio Table 110. Crown Laboratories Inc. Recent Development Table 111. Encore Dermatology, Inc. Company Information Table 112. Encore Dermatology, Inc. Business Overview Table 113. Encore Dermatology, Inc. Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Encore Dermatology, Inc. Semi-Solid Dosage Form Product Portfolio Table 115. Encore Dermatology, Inc. Recent Development Table 116. Glenmark Pharmaceuticals Company Information Table 117. Glenmark Pharmaceuticals Business Overview Table 118. Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Portfolio Table 120. Glenmark Pharmaceuticals Recent Development Table 121. Hisamitsu Pharmaceutical Company Information Table 122. Hisamitsu Pharmaceutical Business Overview Table 123. Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Portfolio Table 125. Hisamitsu Pharmaceutical Recent Development Table 126. Ingenus Pharmaceuticals Company Information Table 127. Ingenus Pharmaceuticals Business Overview Table 128. Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Portfolio Table 130. Ingenus Pharmaceuticals Recent Development Table 131. LEO Pharma Company Information Table 132. LEO Pharma Business Overview Table 133. LEO Pharma Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. LEO Pharma Semi-Solid Dosage Form Product Portfolio Table 135. LEO Pharma Recent Development Table 136. Mylan N.V. Company Information Table 137. Mylan N.V. Business Overview Table 138. Mylan N.V. Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Mylan N.V. Semi-Solid Dosage Form Product Portfolio Table 140. Mylan N.V. Recent Development Table 141. Novartis AG Company Information Table 142. Novartis AG Business Overview Table 143. Novartis AG Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Novartis AG Semi-Solid Dosage Form Product Portfolio Table 145. Novartis AG Recent Development Table 146. Perrigo Pharma Company Information Table 147. Perrigo Pharma Business Overview Table 148. Perrigo Pharma Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Perrigo Pharma Semi-Solid Dosage Form Product Portfolio Table 150. Perrigo Pharma Recent Development Table 151. Taro Pharmaceutical Industries Ltd. Company Information Table 152. Taro Pharmaceutical Industries Ltd. Business Overview Table 153. Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Portfolio Table 155. Taro Pharmaceutical Industries Ltd. Recent Development Table 156. Teligent Pharma Company Information Table 157. Teligent Pharma Business Overview Table 158. Teligent Pharma Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Teligent Pharma Semi-Solid Dosage Form Product Portfolio Table 160. Teligent Pharma Recent Development Table 161. Bayer AG Company Information Table 162. Bayer AG Business Overview Table 163. Bayer AG Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. Bayer AG Semi-Solid Dosage Form Product Portfolio Table 165. Bayer AG Recent Development Table 166. GlaxoSmithKline plc Company Information Table 167. GlaxoSmithKline plc Business Overview Table 168. GlaxoSmithKline plc Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 169. GlaxoSmithKline plc Semi-Solid Dosage Form Product Portfolio Table 170. GlaxoSmithKline plc Recent Development Table 171. Merck & Co Company Information Table 172. Merck & Co Business Overview Table 173. Merck & Co Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 174. Merck & Co Semi-Solid Dosage Form Product Portfolio Table 175. Merck & Co Recent Development Table 176. Johnson & Johnson Company Information Table 177. Johnson & Johnson Business Overview Table 178. Johnson & Johnson Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 179. Johnson & Johnson Semi-Solid Dosage Form Product Portfolio Table 180. Johnson & Johnson Recent Development Table 181. Nestlé SA Company Information Table 182. Nestlé SA Business Overview Table 183. Nestlé SA Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 184. Nestlé SA Semi-Solid Dosage Form Product Portfolio Table 185. Nestlé SA Recent Development Table 186. Sun Pharmaceuticals Company Information Table 187. Sun Pharmaceuticals Business Overview Table 188. Sun Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 189. Sun Pharmaceuticals Semi-Solid Dosage Form Product Portfolio Table 190. Sun Pharmaceuticals Recent Development Table 191. Key Raw Materials Table 192. Raw Materials Key Suppliers Table 193. Semi-Solid Dosage Form Distributors List Table 194. Semi-Solid Dosage Form Customers List Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. Semi-Solid Dosage Form Product Image Figure 2. Global Semi-Solid Dosage Form Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Semi-Solid Dosage Form Market Size (2021-2032) & (US$ Million) Figure 4. Global Semi-Solid Dosage Form Sales (2021-2032) & (K Units) Figure 5. Global Semi-Solid Dosage Form Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Semi-Solid Dosage Form Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ointments Image Figure 9. Gels Image Figure 10. Others Image Figure 11. Global Semi-Solid Dosage Form Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Semi-Solid Dosage Form Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Semi-Solid Dosage Form Sales Market Share by Type (2021-2032) Figure 14. Global Semi-Solid Dosage Form Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Semi-Solid Dosage Form Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Semi-Solid Dosage Form Revenue Market Share by Type (2021-2032) Figure 17. Nasal Cavity Image Figure 18. Skin Image Figure 19. Vaginal Cavity Image Figure 20. Rectal Cavity Image Figure 21. Others Image Figure 22. Global Semi-Solid Dosage Form Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Semi-Solid Dosage Form Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Semi-Solid Dosage Form Sales Market Share by Application (2021-2032) Figure 25. Global Semi-Solid Dosage Form Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Semi-Solid Dosage Form Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Semi-Solid Dosage Form Revenue Market Share by Application (2021-2032) Figure 28. North America Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Semi-Solid Dosage Form Sales Market Share by Country (2021-2032) Figure 30. U.S. Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Semi-Solid Dosage Form Sales Market Share by Country (2021-2032) Figure 35. Germany Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Semi-Solid Dosage Form Sales Market Share by Country (2021-2032) Figure 42. China Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Semi-Solid Dosage Form Sales Market Share by Country (2021-2032) Figure 50. Brazil Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Semi-Solid Dosage Form Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Semi-Solid Dosage Form Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Semi-Solid Dosage Form Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Figure 61. North America Semi-Solid Dosage Form Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Figure 63. Europe Semi-Solid Dosage Form Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Semi-Solid Dosage Form Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Semi-Solid Dosage Form Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Semi-Solid Dosage Form Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Semi-Solid Dosage Form Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Ointments
  • Gels
  • Others
Applications
  • Nasal Cavity
  • Skin
  • Vaginal Cavity
  • Rectal Cavity
  • Others
Companies covered
  • Aclaris Therapeutics, Inc.
  • Akorn Inc. (US)
  • Allergan plc
  • Almirall, S.A
  • Bausch Health Companies
  • Biofrontera, Inc.
  • Cipla Ltd
  • Crescita Therapeutics Inc.
  • Crown Laboratories Inc.
  • Encore Dermatology, Inc.
  • Glenmark Pharmaceuticals
  • Hisamitsu Pharmaceutical
  • Ingenus Pharmaceuticals
  • LEO Pharma
  • Mylan N.V.
  • Novartis AG
  • Perrigo Pharma
  • Taro Pharmaceutical Industries Ltd.
  • Teligent Pharma
  • Bayer AG
  • GlaxoSmithKline plc
  • Merck & Co
  • Johnson & Johnson
  • Nestlé SA
  • Sun Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Semi-Solid Dosage Form Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Semi-Solid Dosage Form Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Semi-Solid Dosage Form Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Semi-Solid Dosage Form Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Semi-Solid Dosage Form Market Dynamics
  1. 2.1 Semi-Solid Dosage Form Industry Trends
  2. 2.2 Semi-Solid Dosage Form Industry Drivers
  3. 2.3 Semi-Solid Dosage Form Industry Opportunities and Challenges
  4. 2.4 Semi-Solid Dosage Form Industry Restraints
3 Semi-Solid Dosage Form Market by Manufacturers
  1. 3.1 Global Semi-Solid Dosage Form Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Semi-Solid Dosage Form Sales by Manufacturers (2021-2026)
  3. 3.3 Global Semi-Solid Dosage Form Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Semi-Solid Dosage Form Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Semi-Solid Dosage Form Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Semi-Solid Dosage Form Manufacturers, Product Type & Application
  7. 3.7 Global Semi-Solid Dosage Form Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Semi-Solid Dosage Form Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Semi-Solid Dosage Form Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Semi-Solid Dosage Form Tier 1, Tier 2, and Tier 3
4 Semi-Solid Dosage Form Market by Type
  1. 4.1 Semi-Solid Dosage Form Type Introduction
  2. 4.1.1 Ointments
  3. 4.1.2 Gels
  4. 4.1.3 Others
  5. 4.2 Global Semi-Solid Dosage Form Sales by Type
  6. 4.2.1 Global Semi-Solid Dosage Form Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Semi-Solid Dosage Form Sales by Type (2021-2032)
  8. 4.2.3 Global Semi-Solid Dosage Form Sales Market Share by Type (2021-2032)
  9. 4.3 Global Semi-Solid Dosage Form Revenue by Type
  10. 4.3.1 Global Semi-Solid Dosage Form Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Semi-Solid Dosage Form Revenue by Type (2021-2032)
  12. 4.3.3 Global Semi-Solid Dosage Form Revenue Market Share by Type (2021-2032)
5 Semi-Solid Dosage Form Market by Application
  1. 5.1 Semi-Solid Dosage Form Application Introduction
  2. 5.1.1 Nasal Cavity
  3. 5.1.2 Skin
  4. 5.1.3 Vaginal Cavity
  5. 5.1.4 Rectal Cavity
  6. 5.1.5 Others
  7. 5.2 Global Semi-Solid Dosage Form Sales by Application
  8. 5.2.1 Global Semi-Solid Dosage Form Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Semi-Solid Dosage Form Sales by Application (2021-2032)
  10. 5.2.3 Global Semi-Solid Dosage Form Sales Market Share by Application (2021-2032)
  11. 5.3 Global Semi-Solid Dosage Form Revenue by Application
  12. 5.3.1 Global Semi-Solid Dosage Form Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Semi-Solid Dosage Form Revenue by Application (2021-2032)
  14. 5.3.3 Global Semi-Solid Dosage Form Revenue Market Share by Application (2021-2032)
6 Global Semi-Solid Dosage Form Sales by Region
  1. 6.1 Global Semi-Solid Dosage Form Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Semi-Solid Dosage Form Sales by Region (2021-2032)
  3. 6.2.1 Global Semi-Solid Dosage Form Sales by Region (2021-2026)
  4. 6.2.2 Global Semi-Solid Dosage Form Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Semi-Solid Dosage Form Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Semi-Solid Dosage Form Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Semi-Solid Dosage Form Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Semi-Solid Dosage Form Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Semi-Solid Dosage Form Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Semi-Solid Dosage Form Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Semi-Solid Dosage Form Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Semi-Solid Dosage Form Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Semi-Solid Dosage Form Revenue by Region
  1. 7.1 Global Semi-Solid Dosage Form Revenue by Region
  2. 7.1.1 Global Semi-Solid Dosage Form Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Semi-Solid Dosage Form Revenue by Region (2021-2026)
  4. 7.1.3 Global Semi-Solid Dosage Form Revenue by Region (2027-2032)
  5. 7.1.4 Global Semi-Solid Dosage Form Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Semi-Solid Dosage Form Revenue (2021-2032)
  8. 7.2.2 North America Semi-Solid Dosage Form Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Semi-Solid Dosage Form Revenue (2021-2032)
  11. 7.3.2 Europe Semi-Solid Dosage Form Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Semi-Solid Dosage Form Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Semi-Solid Dosage Form Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Semi-Solid Dosage Form Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Semi-Solid Dosage Form Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Aclaris Therapeutics, Inc.
  2. 8.1.1 Aclaris Therapeutics, Inc. Company Information
  3. 8.1.2 Aclaris Therapeutics, Inc. Business Overview
  4. 8.1.3 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Portfolio
  6. 8.1.5 Aclaris Therapeutics, Inc. Recent Developments
  7. 8.2 Akorn Inc. (US)
  8. 8.2.1 Akorn Inc. (US) Company Information
  9. 8.2.2 Akorn Inc. (US) Business Overview
  10. 8.2.3 Akorn Inc. (US) Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Akorn Inc. (US) Semi-Solid Dosage Form Product Portfolio
  12. 8.2.5 Akorn Inc. (US) Recent Developments
  13. 8.3 Allergan plc
  14. 8.3.1 Allergan plc Company Information
  15. 8.3.2 Allergan plc Business Overview
  16. 8.3.3 Allergan plc Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Allergan plc Semi-Solid Dosage Form Product Portfolio
  18. 8.3.5 Allergan plc Recent Developments
  19. 8.4 Almirall, S.A
  20. 8.4.1 Almirall, S.A Company Information
  21. 8.4.2 Almirall, S.A Business Overview
  22. 8.4.3 Almirall, S.A Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Almirall, S.A Semi-Solid Dosage Form Product Portfolio
  24. 8.4.5 Almirall, S.A Recent Developments
  25. 8.5 Bausch Health Companies
  26. 8.5.1 Bausch Health Companies Company Information
  27. 8.5.2 Bausch Health Companies Business Overview
  28. 8.5.3 Bausch Health Companies Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bausch Health Companies Semi-Solid Dosage Form Product Portfolio
  30. 8.5.5 Bausch Health Companies Recent Developments
  31. 8.6 Biofrontera, Inc.
  32. 8.6.1 Biofrontera, Inc. Company Information
  33. 8.6.2 Biofrontera, Inc. Business Overview
  34. 8.6.3 Biofrontera, Inc. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Biofrontera, Inc. Semi-Solid Dosage Form Product Portfolio
  36. 8.6.5 Biofrontera, Inc. Recent Developments
  37. 8.7 Cipla Ltd
  38. 8.7.1 Cipla Ltd Company Information
  39. 8.7.2 Cipla Ltd Business Overview
  40. 8.7.3 Cipla Ltd Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Cipla Ltd Semi-Solid Dosage Form Product Portfolio
  42. 8.7.5 Cipla Ltd Recent Developments
  43. 8.8 Crescita Therapeutics Inc.
  44. 8.8.1 Crescita Therapeutics Inc. Company Information
  45. 8.8.2 Crescita Therapeutics Inc. Business Overview
  46. 8.8.3 Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Portfolio
  48. 8.8.5 Crescita Therapeutics Inc. Recent Developments
  49. 8.9 Crown Laboratories Inc.
  50. 8.9.1 Crown Laboratories Inc. Company Information
  51. 8.9.2 Crown Laboratories Inc. Business Overview
  52. 8.9.3 Crown Laboratories Inc. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Crown Laboratories Inc. Semi-Solid Dosage Form Product Portfolio
  54. 8.9.5 Crown Laboratories Inc. Recent Developments
  55. 8.10 Encore Dermatology, Inc.
  56. 8.10.1 Encore Dermatology, Inc. Company Information
  57. 8.10.2 Encore Dermatology, Inc. Business Overview
  58. 8.10.3 Encore Dermatology, Inc. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Encore Dermatology, Inc. Semi-Solid Dosage Form Product Portfolio
  60. 8.10.5 Encore Dermatology, Inc. Recent Developments
  61. 8.11 Glenmark Pharmaceuticals
  62. 8.11.1 Glenmark Pharmaceuticals Company Information
  63. 8.11.2 Glenmark Pharmaceuticals Business Overview
  64. 8.11.3 Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
  66. 8.11.5 Glenmark Pharmaceuticals Recent Developments
  67. 8.12 Hisamitsu Pharmaceutical
  68. 8.12.1 Hisamitsu Pharmaceutical Company Information
  69. 8.12.2 Hisamitsu Pharmaceutical Business Overview
  70. 8.12.3 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Portfolio
  72. 8.12.5 Hisamitsu Pharmaceutical Recent Developments
  73. 8.13 Ingenus Pharmaceuticals
  74. 8.13.1 Ingenus Pharmaceuticals Company Information
  75. 8.13.2 Ingenus Pharmaceuticals Business Overview
  76. 8.13.3 Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
  78. 8.13.5 Ingenus Pharmaceuticals Recent Developments
  79. 8.14 LEO Pharma
  80. 8.14.1 LEO Pharma Company Information
  81. 8.14.2 LEO Pharma Business Overview
  82. 8.14.3 LEO Pharma Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 LEO Pharma Semi-Solid Dosage Form Product Portfolio
  84. 8.14.5 LEO Pharma Recent Developments
  85. 8.15 Mylan N.V.
  86. 8.15.1 Mylan N.V. Company Information
  87. 8.15.2 Mylan N.V. Business Overview
  88. 8.15.3 Mylan N.V. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Mylan N.V. Semi-Solid Dosage Form Product Portfolio
  90. 8.15.5 Mylan N.V. Recent Developments
  91. 8.16 Novartis AG
  92. 8.16.1 Novartis AG Company Information
  93. 8.16.2 Novartis AG Business Overview
  94. 8.16.3 Novartis AG Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Novartis AG Semi-Solid Dosage Form Product Portfolio
  96. 8.16.5 Novartis AG Recent Developments
  97. 8.17 Perrigo Pharma
  98. 8.17.1 Perrigo Pharma Company Information
  99. 8.17.2 Perrigo Pharma Business Overview
  100. 8.17.3 Perrigo Pharma Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Perrigo Pharma Semi-Solid Dosage Form Product Portfolio
  102. 8.17.5 Perrigo Pharma Recent Developments
  103. 8.18 Taro Pharmaceutical Industries Ltd.
  104. 8.18.1 Taro Pharmaceutical Industries Ltd. Company Information
  105. 8.18.2 Taro Pharmaceutical Industries Ltd. Business Overview
  106. 8.18.3 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Portfolio
  108. 8.18.5 Taro Pharmaceutical Industries Ltd. Recent Developments
  109. 8.19 Teligent Pharma
  110. 8.19.1 Teligent Pharma Company Information
  111. 8.19.2 Teligent Pharma Business Overview
  112. 8.19.3 Teligent Pharma Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Teligent Pharma Semi-Solid Dosage Form Product Portfolio
  114. 8.19.5 Teligent Pharma Recent Developments
  115. 8.20 Bayer AG
  116. 8.20.1 Bayer AG Company Information
  117. 8.20.2 Bayer AG Business Overview
  118. 8.20.3 Bayer AG Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Bayer AG Semi-Solid Dosage Form Product Portfolio
  120. 8.20.5 Bayer AG Recent Developments
  121. 8.21 GlaxoSmithKline plc
  122. 8.21.1 GlaxoSmithKline plc Company Information
  123. 8.21.2 GlaxoSmithKline plc Business Overview
  124. 8.21.3 GlaxoSmithKline plc Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 GlaxoSmithKline plc Semi-Solid Dosage Form Product Portfolio
  126. 8.21.5 GlaxoSmithKline plc Recent Developments
  127. 8.22 Merck & Co
  128. 8.22.1 Merck & Co Company Information
  129. 8.22.2 Merck & Co Business Overview
  130. 8.22.3 Merck & Co Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Merck & Co Semi-Solid Dosage Form Product Portfolio
  132. 8.22.5 Merck & Co Recent Developments
  133. 8.23 Johnson & Johnson
  134. 8.23.1 Johnson & Johnson Company Information
  135. 8.23.2 Johnson & Johnson Business Overview
  136. 8.23.3 Johnson & Johnson Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Johnson & Johnson Semi-Solid Dosage Form Product Portfolio
  138. 8.23.5 Johnson & Johnson Recent Developments
  139. 8.24 Nestlé SA
  140. 8.24.1 Nestlé SA Company Information
  141. 8.24.2 Nestlé SA Business Overview
  142. 8.24.3 Nestlé SA Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Nestlé SA Semi-Solid Dosage Form Product Portfolio
  144. 8.24.5 Nestlé SA Recent Developments
  145. 8.25 Sun Pharmaceuticals
  146. 8.25.1 Sun Pharmaceuticals Company Information
  147. 8.25.2 Sun Pharmaceuticals Business Overview
  148. 8.25.3 Sun Pharmaceuticals Semi-Solid Dosage Form Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Sun Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
  150. 8.25.5 Sun Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Semi-Solid Dosage Form Value Chain Analysis
  2. 9.1.1 Semi-Solid Dosage Form Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Semi-Solid Dosage Form Production Mode & Process
  6. 9.2 Semi-Solid Dosage Form Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Semi-Solid Dosage Form Distributors
  9. 9.2.3 Semi-Solid Dosage Form Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst